Ibrahim Musa | Molecular Physiology | Best Researcher Award

Dr. Ibrahim Musa | Molecular Physiology | Best Researcher Award

Prince Abubakar Audu University | Nigeria

Dr. Ibrahim Musa is a Molecular Physiologist with a PhD in Molecular Physiology and Biochemistry from the University of Birmingham, UK, where his doctoral research focused on the molecular function and stability of MuRF1 in skeletal muscle using CRISPR/Cas9 and retroviral applications. He has over four years of research experience in ubiquitin biology, target validation, cellular biology, and molecular mechanisms, with expertise in CRISPR/Cas9 gene-editing and primary human skeletal muscle culture. As a Research Assistant at the Cellular Health and Metabolism Facility, University of Birmingham, he screened novel drug compounds for mitochondrial dysfunction and optimized dose-response assays in human myoblasts. Dr. Musa has also served as a Lecturer and Researcher in Human Physiology at Kogi State University, Nigeria, for a decade, where he has designed curricula, delivered undergraduate and MBBS lectures, supervised laboratory sessions, and coordinated departmental seminars. His research contributions are published in reputable journals, with an h-index of X, over Y documents, and more than Z citations indexed in Scopus/Google Scholar. He has been recognized with prestigious awards, including the TETFund Doctoral Scholarship (£99,960) and multiple travel awards from the Physiological Society and University of Birmingham, underscoring his growing impact in molecular physiology and biomedical research.

Profiles: Google Scholar | Orcid

Featured Publications:

Gant, H., Ghimire, N., Min, K., Musa, I., Ashraf, M., & Lawan, A. (2024). Impact of the quadriceps angle on health and injury risk in female athletes. International Journal of Environmental Research and Public Health, 21(12), 1547.

Musa, I., et al. (2025). MuRF1 partners with TRIM72 E3 ligases to impair insulin sensitivity in skeletal muscle. FASEB Journal. (Accepted; preprint available at bioRxiv).

Nishimura, Y., Chunthorng-Orn, J., Lord, S., Musa, I., Dawson, P., Holm, L., & Lai, Y. C. (2022). Ubiquitin E3 ligase Atrogin-1 protein is regulated via the rapamycin-sensitive mTOR-S6K1 signalling pathway in C2C12 muscle cells. American Journal of Physiology-Cell Physiology, 323(1), C215–C225.

Nishimura, Y., Musa, I., Holm, L., & Lai, Y. C. (2021). Recent advances in measuring and understanding the regulation of exercise-mediated protein degradation in skeletal muscle. American Journal of Physiology-Cell Physiology, 321(2), C276–C287.

Seabright, A. P., Fine, N. H. F., Barlow, J. P., Lord, S. O., Musa, I., Gray, A., Bryant, J., Banzhaf, M., Lavery, G. G., Hardie, D. G., Hodson, D. J., Philp, A., & Lai, Y. C. (2020). AMPK activation induces mitophagy and promotes mitochondrial fission while activating TBK1 in a PINK1-Parkin independent manner. The FASEB Journal, 34(11), 14416–14433.

Ju Cao | Medical Laboratory Science | Best Researcher Award

Prof. Ju Cao | Medical Laboratory Science | Best Researcher Award

Prof. Ju Cao , The First Affiliated Hospital of Chongqing Medical University , China

Ju Cao is a renowned professor at The First Affiliated Hospital of Chongqing Medical University, China, and a leading expert in the field of infectious diseases and sepsis. As a graduate supervisor and professor, Dr. Cao has been recognized for his significant contributions to scientific and technological innovation in China. His research primarily focuses on the development and application of biomarkers in diagnosing and understanding organ damage in infectious diseases, especially sepsis. Over the years, Dr. Cao has published over 30 SCI papers in prestigious international journals and holds several patents. He serves as an editorial board member of The Clinical Respiratory Journal and is actively involved in national and international research collaborations. His innovative work has garnered attention for its potential to improve patient outcomes through early diagnosis and treatment of sepsis and other infectious diseases.

Publication Profile:

Scopus

Strengths for the Award:

Ju Cao is a distinguished scholar in the field of infectious diseases and sepsis, contributing significantly to the identification and development of biomarkers for diagnosing, monitoring, and prognosticating these conditions. As a professor at The First Affiliated Hospital of Chongqing Medical University, he has demonstrated leadership and excellence in both research and academic mentorship. He has published over 100 research articles, including impactful works in high-profile journals such as Sci Transl Med, Am J Respir Crit Care Med, and Gut Microbes. His work on immune regulatory mechanisms, molecular diagnostics, and therapeutic biomarkers has proven essential for advancing the treatment and prevention of sepsis and related infections. Furthermore, Ju Cao’s collaboration in major national and international research projects has led to numerous groundbreaking findings in the field.

Areas for Improvement:

While Ju Cao’s focus on diagnostic biomarkers is highly impactful, there may be room for a deeper integration of translational research that bridges the gap between laboratory findings and clinical applications. Additionally, more interdisciplinary collaborations that extend his research into other infectious diseases or global health challenges could enhance the scope and application of his work.

Education:

Dr. Ju Cao holds a distinguished academic background in the medical field, with a focus on immunology and clinical diagnostics. His early education in medicine laid a solid foundation for his career, later transitioning to advanced studies in immunology and infectious diseases. After completing his medical degree, Dr. Cao pursued postgraduate research in biomarker development, focusing on the intersection of immune responses and infectious diseases. He has continually enhanced his expertise through various international collaborations and research initiatives, particularly in sepsis, organ damage, and immune system modulation. His commitment to advancing the understanding of infectious diseases has been bolstered by his ongoing contributions to both academic and practical applications in medical diagnostics. Dr. Cao’s educational journey is a testament to his dedication to advancing medical science and improving patient care through innovative research and leadership in his field.

Experience:

Dr. Ju Cao is a professor at The First Affiliated Hospital of Chongqing Medical University, where he has played a key role in research, mentorship, and clinical advancement. He is recognized as a leading talent in scientific and technological innovation in China. With a research career spanning several years, Dr. Cao has been the principal investigator for numerous national and international research projects focusing on infectious diseases and sepsis. He has contributed to over 30 influential publications in prominent international journals, including Am J Respir Crit Care Med, EMBO Mol Med, and Plos Pathog. In addition to his research accomplishments, Dr. Cao holds leadership roles in several professional societies, including the Chinese Society of Laboratory Medicine and the Chinese Medical Doctor Association. His expertise in biomarker discovery has significantly influenced the clinical management of infectious diseases and sepsis, making him a respected figure in the medical community both nationally and globally.

Research Focus:

Dr. Ju Cao’s research focuses on the diagnosis and prognosis of infectious diseases, particularly sepsis, and the role of biomarkers in these processes. His work has significantly contributed to understanding the molecular mechanisms behind organ damage in sepsis, with a primary emphasis on immune system regulation. Dr. Cao’s studies explore the development and application of biomarkers to improve early diagnosis, monitor therapeutic responses, and predict patient outcomes in sepsis and other infectious diseases. Through his research, he has contributed to uncovering immune regulatory pathways and identifying novel therapeutic targets, such as interleukins and other immune modulators. His ongoing projects include exploring the roles of interleukin-27, CXCL13, and progranulin in the progression and treatment of sepsis. Additionally, Dr. Cao is involved in advancing the clinical application of these biomarkers to help improve survival rates and treatment efficacy for patients suffering from severe infections, making a lasting impact on global healthcare.

Publication Top Notes:

  1. “Bone morphogenetic protein 9 is a candidate prognostic biomarker and host-directed therapy target for sepsis” 🌟
  2. “Progranulin protects against Clostridioides difficile infection by enhancing IL-22 production” 🔬
  3. “Progranulin Plays a Central Role in Host Defense during Sepsis by Promoting Macrophage Recruitment” 🦠
  4. “Apoptosis inhibitor of macrophage differentiates bacteria from influenza or COVID-19 in hospitalized adults with community-acquired pneumonia” 💉
  5. “Interleukin-37 as a biomarker of mortality risk in patients with sepsis” ⚠️

Conclusion:

Ju Cao is undoubtedly a strong candidate for the Best Researcher Award. His extensive research output, leadership in the field, and contributions to the understanding and treatment of infectious diseases and sepsis highlight his exceptional expertise and dedication. His innovative approach to diagnostics and therapy, coupled with his consistent track record of influential publications, makes him a deserving nominee for this prestigious award.